

## **SUPPLEMENTARY DATA**


# **Rational engineering of a native hyperthermostable lactonase into a broad spectrum phosphotriesterase**

Pauline Jacquet<sup>1○</sup>, Julien Hiblot<sup>1†○</sup>, David Daudé<sup>2○</sup>, Céline Bergonzi<sup>1,3</sup>, Guillaume Gotthard<sup>1</sup>, Nicholas Armstrong<sup>1</sup>, Eric Chabrière<sup>1#</sup>, Mikael Elias<sup>3#</sup>


1 - CNRS UMR 7278, IRD198, INSERM U1095, APHM, Institut Hospitalier Universitaire Méditerranée-Infection, Aix-Marseille Université, 19-21 Bd Jean Moulin 13005 Marseille, France.

2 - Gene&GreenTK, IHU Méditerranée Infection, 19-21 Bd Jean Moulin, 13005 Marseille, France


3 - University of Minnesota, Department of Biochemistry, Molecular Biology and Biophysics & Biotechnology Institute, St. Paul, MN 55108, USA




**Figure S1: Structure-based active site cavity redesign.** Active site cavity view of (A) *wt* *SsoPox*, (B) *BdPTE* and (C) *SsoPox* modelled with all 14 designed mutations (Table S1). The mutations modelled were constructed *in silico* and energy was minimized using *Swiss PDB viewer*.<sup>59</sup> Electrostatic potentials were calculated using PyMOL<sup>60</sup> and are shown on the molecular surface. Electrostatic potentials are represented at the enzyme's surfaces. Blue, red and white indicates positively-, negatively-, and neutrally-charged areas, respectively.




**Figure S2: Library screening data.** (A) Occurrence of mutations in the 14 best sequenced clones. (B) Screening profile of the combinatorial mutation library (184 clones) with paraoxon as a substrate. Activities ( $\text{mOD}_{405\text{nm}} \text{ min}^{-1}$ ) were normalized to the median value. (C) Screening of the position 263 saturation library ( $\alpha$ sB5 background) with paraoxon as the substrate. Activity was normalized to  $\alpha$ sB5 paraoxonase activity.




**Figure S3. Chlorferon vs Fluorescence (360 (40) / 460 (40)) range of linearity**




**Figure S4. Bioremediation of organophosphorus insecticides (250  $\mu$ M)**



**Figure S5. Structural superposition of wt-SsoPox and mutants dimers.** The monomers on the right were superimposed, and the difference with the left monomers indicates the relative reorientation of dimerized monomers. (A) Superposition of wt-SsoPox (green) and  $\alpha$ sA1 (orange). (B) Superposition of wt-SsoPox (green) and  $\alpha$ sB5 (yellow). (C) Superposition of wt-SsoPox (green) and  $\alpha$ sC6 (blue). (D) Superposition of wt-SsoPox (green) and  $\alpha$ sD6 (brown). (E) Superposition of wt-SsoPox (green) and  $\alpha$ sA6-CC (cyan). (F) Superposition of wt-SsoPox (green) and  $\alpha$ sA6-OC (magenta). (G) Superposition of  $\alpha$ sA6-OC (magenta) and  $\alpha$ sA6-CC (cyan). (H) Superposition of wt-SsoPox (green),  $\alpha$ sA1 (orange),  $\alpha$ sB5 (yellow),  $\alpha$ sD6 (brown),  $\alpha$ sC6 (blue),  $\alpha$ sA6-OC (magenta) and  $\alpha$ sA6-CC (cyan).



**Figure S6. Mutant  $\alpha$ sA6 loop-8 conformational flexibility.** **(A)** Superposition of the open conformation (OC, blue) and the closed conformation (CC, magenta), of loop 8 in two distinct mutant  $\alpha$ sA6 crystal structures. **(B)** Location of the four mutations of mutant  $\alpha$ sA6 in the structure. The wt *SsoPox*, the CC, and the OC loop 8 conformations are shown in green, magenta and blue, respectively. We note that I280T and C258S are located at the very beginning and end of loop 8. **(C)** Positional distributions of normalized B-factor values (the x-axis represents residue number) for wt-*SsoPox* (black line),  $\alpha$ sA6-OC (blue line) and ( $\alpha$ sA6-CC magenta line).



**Figure S7: Thiono-effect in *SsoPox*.** Catalytic efficiencies of enzymes, *SsoPox*, *BdPTE* and *SsoPox-asD6* with methyl-paraoxon (black) and methyl-parathion (gray) as substrates are shown.

**Table S1: Mutation database**

	SsoPox position	Corresponding position in BdPTE	Redesign	Additional mutations	Mutations in database
First set of mutations	V27	G60	-	-	V27A
	P67	V101	-	-	P67V
	T68	S102	-	-	T68S
	L72	I106	-	-	L72I
	Y97	W131	-	-	Y97W
	D141	T173	-	-	D141T
	G225	P256	-	-	G225P
	L226	H257	-	-	L226H
	C258	L303	-	A	C258/A-L
	I261	F306	-	-	I261F
Second set of mutations	Y99	-	F	-	Y99F
	L228	-	M	-	L228M
	F229	-	S	-	F229S
	W263	-	A	Saturation	W263/All

**Table S2: Oligonucleotide sequences used in this study**

Primer name		Primer sequence
Clonage	T7-prom	TAA TAC GAC TCA CTA TAG GG
	pET-RP	GCT AGT TAT TGC TCA GCG G
	SsoPox-lib-pET-5'	CAT GCC ATG GCG CGC ATT CCG CTG GTT GGT AAA G
	SsoPox-lib-pET-3'	AAG GAA AAA AGC GGC CGC TTA TTA GCT AAA GAA TTT TTT CGG ATT TTC
Primer name	Encoding variation	Primer sequence
Primers used in ISOR protocol	SP1	GAA CAT CTG CGT GCA TTT AGC GAA GCA GTT
	SP2	AAA ACC ATT GTT GAT GTG AGT GTT ATG GGT
	SP3	AAA ACC ATT GTT GAT GTG ACC GTT ATG GGT
	SP4	AAA ACC ATT GTT GAT CCG AGT GTT ATG GGT
	SP5	GTT ATG GGT ATT GGT CGT GAT ATT CGT TTT
	SP6	GGC ACC GGT ATT TGG ATT TTT ATC GAT CTG CCG
	SP7	GGC ACC GGT ATT TGG ATT TAT ATC GAT CTG CCG
	SP8	GGC ACC GGT ATT TAT ATT TTT ATC GAT CTG CCG
	SP9	AAA ATT GCA GCC ACC GAA CCG GGT ATT ACC
	SP10	GAT CGT TAT GGT CAC GAC MTG TYT CTG CCG GTT
	SP11	GAT CGT TAT GGT GTG GAC MTG TYT CTG CCG GTT
	SP12	GAT CGT TAT CCG CTG GAC MTG TYT CTG CCG GTT
	SP13	GAT CGT TAT CCG CAC GAC MTG TYT CTG CCG GTT
	SP14	GAT CGT TAT CCG GTG GAC MTG TYT CTG CCG GTT
	SP15	GAT CGT TAT GGT CTG GAC MTG TYT CTG CCG GTT
	SP16	ATT AGC CAT GAT TAT CTG TGC ACC ATT GAT
	SP17	ATT AGC CAT GAT TAT GCC TGC ACC ATT GAT
	SP18	GAT TAT TGC TGC ACC TTT GAT TGG GGC ACC
	SP19	TGC ACC ATT GAT TTT GGC ACC GCA AAA CCG
	SP20	TGC ACC ATT GAT ATG GGC ACC GCA AAA CCG
	SP21	TGC ACC ATT GAT CTG GGC ACC GCA AAA CCG
	SP22	TGC ACC ATT GAT GCG GGC ACC GCA AAA CCG

**Table S3: Selected positions for phosphotriesterase activity improvement**

Position	27	67	68	72	97	99	141	225	226	228	229	258	261	263	Additional	Total variations
<b>wt</b>	V	P	T	L	Y	Y	D	G	I	L	F	C	I	W		
<b>B3</b>	A			I	W					M						V27A/L72I/Y97W/L228M
<b>F2</b>										M				L		L228M/W263L
<b>F8</b>				I										M	K54I	K54I/L72I/W263M
<b>B2</b>	A			I		F	T			M				M	G7S/V28A	G7S/V27A/V83A/L72I/Y99F/D141T/L228M/W263M
<b>H8</b>			S		W	F				M						T68S/Y97W/Y99F/L228M/
<b>E3</b>	A			I										M	V83A/E173T	V27A/L72I/V83A/E173T/W263M
<b>A4</b>					F				M					M	G193S	Y99F/G193S/L228M/W263M
<b>A1</b>											L	F	A			C258L/I261F/W263A
<b>A6</b>											A			M	F46L/I280T	F46L/C258A/W263M/I280T
<b>B5</b>	A				W	F			V						I76T/L130P	V27A/I76T/Y97W/Y99F/L130P/L226V
<b>C6</b>				I		F				M	S			L	I122L	L72I/Y99F/I122L/L228M/F229S/W263L
<b>D6</b>	A				W				M					M		V27A/Y97W/L228M/W263M
<b>D1</b>					W											Y97W
<b>D5</b>				I										F		L72I/W263F
<b>A5</b>	A					F								L		V27A/L72I/Y99F/W263L
<b>Incorporation</b>	6	0	1	6	5	6	1	0	1	7	1	2	1	11		
<b>Ratio</b>	0.4	0	0.07	0.4	0.33	0.4	0.07	0	0.07	0.47	0.07	0.13	0.07	0.73		

**Table S4: Tm values of *SsoPox* variants**

Enzyme	Mutations	T <sub>m</sub> (°C)
<i>wt</i>	*	106
<b>asD6</b>	V27A/Y97W/L228M/W263M	82.5 ± 1,8
<b>asB5</b>	V27A/I76T/Y97W/Y99F/L130P/L226V	70.4 ± 3,1
<b>asB5 W263M</b>	V27A/I76T/Y97W/Y99F/L130P/L226V/W263M	69.1 ± 2,3
<b>asB5 W263L</b>	V27A/I76T/Y97W/Y99F/L130P/L226V/W263L	80.2 ± 4,0
<b>asB5 W263I</b>	V27A/I76T/Y97W/Y99F/L130P/L226V/W263I	77.9 ± 1,3
<b>W263M</b>	W263M	85.3 ± 0,9
<b>W263L</b>	W263L	92.0 ± 2,1

**Melting temperature determination.** Circular Dichroism (CD) spectra were obtained using a Jasco J-815 CD spectrometer with a Pelletier-type temperature control system (Jasco MPTC-490S) in a 1 mm thick quartz Starna® cell and using Spectra Manager software. Experiments were carried out in 10 mM phosphate buffer at pH 8.0. Proteins concentrations were within 0.2–0.4 mg.mL<sup>-1</sup>, denaturation was followed at 222 nm with temperature increased from 25 to 85°C (with 5°C.min<sup>-1</sup> increment). A range of between 0.5 and 3 M of guanidinium chloride in 10 mM phosphate buffer at pH 8.0 was applied. Data were analyzed with GraphPad Prism 6 using Boltzmann sigmoidal equation, and T<sub>m</sub> at 0 M of guanidinium chloride was then extrapolated by linear regression.

### Thermal stability of the engineered variants

We measured the melting temperature of variants  $\alpha$ sD6,  $\alpha$ sB5,  $\alpha$ sB5-W263L,  $\alpha$ sB5-W263M and  $\alpha$ sB5-W263I in this study while the T<sub>m</sub> values of *wt*, W263M and W263L were previously reported (**Table S4**).<sup>7</sup> All variants showed decreased T<sub>m</sub> values as compared to the wild-type enzyme. These values ranged from 69 °C to 92 °C for  $\alpha$ sB5-W263M and W263L, respectively. As previously reported, the role of residue 263 is crucial for overall enzyme stability. The stability of mono-substituted variants was globally less affected than the  $\alpha$ sD6 and  $\alpha$ sB5 scaffolds. The latter's T<sub>m</sub> value decreased by 36 °C as compared to *SsoPox*-WT, while the addition of a mutation at position W263 to its background was not destabilizing, suggesting that their contribution to stability may be different. While the T<sub>m</sub> values for the best variants have decreased, they remain very stable (e.g.  $\alpha$ sD6 has a T<sub>m</sub> of 82.5°C), as compared with their mesophilic counterparts (T<sub>m,BdPTE</sub>=67°C).<sup>61</sup> Additionally, the expression level of the *SsoPox* and its mutants were ≈100-150 mg.l<sup>-1</sup><sub>culture</sub>, a higher level than the *BdPTE* (≈3 mg.l<sup>-1</sup><sub>culture</sub>) and ≈50 mg.l<sup>-1</sup><sub>culture</sub> for the improved *BdPTE-S5* variant.<sup>61</sup>

Interestingly, the range of recognized substrate was broadened when thermostability decreased which is consistent with previous reports suggesting that mutations often increase activity at the cost of stability (**Figure 7**).<sup>62,63</sup>